EVENT DETAILS

Business Plan Presentations:
Biotech Innovators

NexGenix Pharmaceuticals

NexGenix is the first and only company to focus on treatments for neurofibromatosis (NF), genetic tumor suppressor disorders characterized by the development of tumors along nerves. NF affects approximately 100,000 people in the U.S. and 1.6 million people worldwide - more than muscular dystrophy, Huntington's disease and cystic fibrosis combined. NexGenix has integrated all aspects of drug development for NF1 and NF2, from target identification to the clinic.

NexGenix has two treatments in development: a unique formulation and use of a generic drug which has been demonstrated in a small proof of principle clinical trial to be effective; and a drug being developed internally, which it believes will ultimately enable it to reach a market of over $1 billion per year. NexGenix's scientific advisor/founders represent most of the top scientists working on NF in the world. NexGenix has filed patent applications for unique uses for several families of generic drugs to be used in the treatment of NF and for a drug delivery mechanism. NexGenix has raised over $5 million in angel investment, and is presently seeking an additional $6 million to fund the development of its first NF product to the point of entering a phase one trial.

Chrono Therapeutics, Inc.

Chrono Therapeutics, Inc. is the developer of ChronoDose™, a patented transdermal drug delivery technology consisting of a miniaturized, automated, fully programmable, non-invasive device worn on the wrist, the ChronoDose™ system. Chrono Therapeutics has exclusive rights to all ChronoDose™ technology. No other technology currently exists that can administer distinct and varying dosages of medication passively following a pre-programmed dosage profile in an accurate and repeatable fashion. Chrono Therapeutics' transdermal drug delivery (TDD) regimens are derived from Chrono-pharmacology resulting in bio-synchronous dosing. This technology was developed in association with the University of Basel, the oldest University in Europe, and a leader both TDD and Chrono-pharmacology. ChronoDose™ provides for quicker drug absorption in a non-invasive manner. By tailoring the timing and dosing, symptoms can be managed more effectively with fewer side effects. Patient compliance is increased as the system is fully automated. This type of disease management is particularly effective for certain OTC applications, as well as pain management, depression, asthma, arthritis and angina and for those at risk for heart attack and stroke. Chrono Therapeutics has been granted a patent protecting their core technology and over six other patents pending. To date, over $2,000,000 has been invested in the ChronoDose™ system, and Chrono Therapeutics is currently seeking $10 million for the final development, manufacturing, clinical trials and marketing of the ChronoDose™ system.

Ideal Life Inc.

IDEAL LIFE is an interactive communication technology company focused on using real-time, interactive, two-way, wireless communication technologies for solutions that empower individuals to better manage their health and empower providers to offer higher quality, and timelier health care. IDEAL LIFE'S technology is simple and easy to use, as it does not rely on a PC or other complex tools. IDEAL LIFE has initially targeted hypertension and is currently in a program with a large California IPA. The interactive hypertension management tool is a home-use blood pressure/pulse monitor that reports results in real time to health care providers and allows for messaging capabilities. Beginning in the first quarter of 2006, IDEAL LIFE plans to launch its interactive health monitoring and management programs that address the diabetic and obesity markets. The initial market targets are various provider groups, including: insurance companies, managed care providers and employee benefits groups, as well as pharmaceutical companies and weight management companies. IDEAL LIFE has completed the development of its core technology platform, has received approval on its first patent, has other patents pending and has secured agreements with telecommunications providers to support its North American wide network. IDEAL LIFE has been self-funded to date and is currently seeking $4 million for commercialization.

   Sponsors: